{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:17:43Z","timestamp":1792412263152,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prostate cancer is one of the most prevalent malignancies in men, with increasing incidence and mortality largely attributed to treatment resistance and metastasis. The effectiveness of current therapies for advanced cases is hindered by intricate genetic and microenvironmental factors, emphasizing the urgent need for novel therapeutic targets. Chimeric RNAs have emerged as promising biomarkers in cancer research, among which CCDC7\n                    <jats:sub>19-13<\/jats:sub>\n                    , a circular chimeric RNA, is frequently identified in prostate cancer. Our study reveals that CCDC7\n                    <jats:sub>19-13<\/jats:sub>\n                    expression is markedly reduced in advanced and recurrent prostate cancer, where its low levels serve as an independent predictor of poor prognosis. Functional experiments demonstrate that CCDC7\n                    <jats:sub>19-13<\/jats:sub>\n                    overexpression inhibits cell proliferation, induces apoptosis, and suppresses tumor growth in vivo, whereas its knockdown reverses these effects. Mechanistically, CCDC7\n                    <jats:sub>19-13<\/jats:sub>\n                    encodes a novel protein, CCDC7\n                    <jats:sub>241aa<\/jats:sub>\n                    , which triggers ferroptosis by interacting with SLC7A11 and facilitating its TRIM21-mediated ubiquitination and degradation. Notably, treatment with recombinant CCDC7\n                    <jats:sub>241aa<\/jats:sub>\n                    effectively suppresses tumor growth in patient-derived xenograft models without toxicity and enhances the efficacy of docetaxel and enzalutamide in vitro. These findings establish CCDC7\n                    <jats:sub>19-13<\/jats:sub>\n                    as a significant prognostic marker and potential therapeutic target in prostate cancer, with the recombinant CCDC7\n                    <jats:sub>241aa<\/jats:sub>\n                    protein offering promise for combination therapies in advanced cases.\n                  <\/jats:p>","DOI":"10.1038\/s41418-025-01580-x","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:04:59Z","timestamp":1758539099000},"page":"605-625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Induction of ferroptosis in prostate cancer by CCDC719-13 via TRIM21-mediated ubiquitination of SLC7A11"],"prefix":"10.1038","volume":"33","author":[{"given":"Bisheng","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2564-7778","authenticated-orcid":false,"given":"Qiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zean","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunJia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7879-1792","authenticated-orcid":false,"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2013-073X","authenticated-orcid":false,"given":"Hai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"1580_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1580_CR2","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72:409\u201336.","journal-title":"CA Cancer J Clin"},{"key":"1580_CR3","first-page":"568","volume":"20","author":"B Cheng","year":"2023","unstructured":"Cheng B, Huang H. Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment. Cancer Biol Med. 2023;20:568\u201374.","journal-title":"Cancer Biol Med"},{"key":"1580_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet. 2021;398:1075\u201390.","journal-title":"Lancet"},{"key":"1580_CR5","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1097\/JS9.0000000000001308","volume":"110","author":"B Cheng","year":"2024","unstructured":"Cheng B, He H, Chen B, Zhou Q, Luo T, Li K, et al. Assessment of treatment outcomes: cytoreductive surgery compared to radiotherapy in oligometastatic prostate cancer - an in-depth quantitative evaluation and retrospective cohort analysis. Int J Surg. 2024;110:3190\u2013202.","journal-title":"Int J Surg"},{"key":"1580_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2016.07.006","volume":"2","author":"Y Jia","year":"2016","unstructured":"Jia Y, Xie Z, Li H. Intergenically spliced chimeric RNAs in cancer. Trends Cancer. 2016;2:475\u201384.","journal-title":"Trends Cancer"},{"key":"1580_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.gde.2017.10.002","volume":"48","author":"Z Li","year":"2018","unstructured":"Li Z, Qin F, Li H. Chimeric RNAs and their implications in cancer. Curr Opin Genet Dev. 2018;48:36\u201343.","journal-title":"Curr Opin Genet Dev"},{"key":"1580_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.gendis.2019.08.002","volume":"6","author":"H Wu","year":"2019","unstructured":"Wu H, Li X, Li H. Gene fusions and chimeric RNAs, and their implications in cancer. Genes Dis. 2019;6:385\u201390.","journal-title":"Genes Dis"},{"key":"1580_CR9","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/nar\/gkz1223","volume":"48","author":"S Singh","year":"2020","unstructured":"Singh S, Qin F, Kumar S, Elfman J, Lin E, Pham LP, et al. The landscape of chimeric RNAs in non-diseased tissues and cells. Nucleic Acids Res. 2020;48:1764\u201378.","journal-title":"Nucleic Acids Res"},{"key":"1580_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1777","volume":"14","author":"S Mukherjee","year":"2023","unstructured":"Mukherjee S, Mukherjee SB, Frenkel-Morgenstern M. Functional and regulatory impact of chimeric RNAs in human normal and cancer cells. Wiley Interdiscip Rev RNA. 2023;14:e1777.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"1580_CR11","doi-asserted-by":"publisher","first-page":"11377","DOI":"10.1073\/pnas.97.21.11377","volume":"97","author":"L Conforti","year":"2000","unstructured":"Conforti L, Tarlton A, Mack TG, Mi W, Buckmaster EA, Wagner D, et al. A Ufd2\/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse. Proc Natl Acad Sci USA. 2000;97:11377\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1580_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00503-2","volume":"8","author":"Q Wang","year":"2024","unstructured":"Wang Q, Cheng B, Singh S, Tao Y, Xie Z, Qin F, et al. A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3. NPJ Precis Oncol. 2024;8:11.","journal-title":"NPJ Precis Oncol"},{"key":"1580_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13578-022-00893-5","volume":"12","author":"Q Wang","year":"2022","unstructured":"Wang Q, Chen J, Singh S, Xie Z, Qin F, Shi X, et al. Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer. Cell Biosci. 2022;12:153.","journal-title":"Cell Biosci"},{"key":"1580_CR14","doi-asserted-by":"publisher","first-page":"217938","DOI":"10.1016\/j.canlet.2025.217938","volume":"631","author":"B Cheng","year":"2025","unstructured":"Cheng B, Luo T, Wu Y, Hu J, Yang C, Wu J, et al. Urinary exosomal FAM153C-RPL19 chimeric RNA as a diagnostic and prognostic biomarker for prostate cancer in Chinese patients. Cancer Lett. 2025;631:217938.","journal-title":"Cancer Lett"},{"key":"1580_CR15","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185:2401\u201321.","journal-title":"Cell"},{"key":"1580_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","volume":"7","author":"W Gao","year":"2022","unstructured":"Gao W, Wang X, Zhou Y, Wang X, Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Sig Transduct Target Ther. 2022;7:196.","journal-title":"Sig Transduct Target Ther"},{"key":"1580_CR17","doi-asserted-by":"crossref","unstructured":"Cheng B, Lai Y, Huang H, Peng S, Tang C, Chen J, et al. MT1G, an emerging ferroptosis-related gene: a novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer. Environ Toxicol. 2024;39:927\u201341.","DOI":"10.1002\/tox.23997"},{"key":"1580_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203973","volume":"10","author":"B Tang","year":"2023","unstructured":"Tang B, Zhu J, Wang Y, Chen W, Fang S, Mao W, et al. Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the Anti-PD-1\/L1 response. Adv Sci. 2023;10:e2203973.","journal-title":"Adv Sci"},{"key":"1580_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22:381\u201396.","journal-title":"Nat Rev Cancer"},{"key":"1580_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13045-022-01392-3","volume":"15","author":"X Tong","year":"2022","unstructured":"Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, et al. Targeting cell death pathways for cancer therapy: Recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol. 2022;15:174.","journal-title":"J Hematol Oncol"},{"key":"1580_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41418-022-01051-7","volume":"30","author":"Q Chen","year":"2023","unstructured":"Chen Q, Zheng W, Guan J, Liu H, Dan Y, Zhu L, et al. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ. 2023;30:137\u201351.","journal-title":"Cell Death Differ"},{"key":"1580_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2023.03.016","volume":"79","author":"F He","year":"2023","unstructured":"He F, Zhang P, Liu J, Wang R, Kaufman RJ, Yaden BC, et al. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J Hepatol. 2023;79:362\u201377.","journal-title":"J Hepatol"},{"key":"1580_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39401-9","volume":"14","author":"Y Yan","year":"2023","unstructured":"Yan Y, Teng H, Hang Q, Kondiparthi L, Lei G, Horbath A, et al. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells. Nat Commun. 2023;14:3673.","journal-title":"Nat Commun"},{"key":"1580_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","volume":"580","author":"J Li","year":"2020","unstructured":"Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580:93\u20139.","journal-title":"Nature"},{"key":"1580_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/JS9.0000000000001968","volume":"111","author":"B Cheng","year":"2025","unstructured":"Cheng B, Li B, Fu J, Wang Q, Luo T, Li Z, et al. Evaluating the effectiveness of cytoreductive surgery in oligometastatic prostate cancer: Insights from quantitative analysis and retrospective cohort studies. Int J Surg. 2025;111:122\u201334.","journal-title":"Int J Surg"},{"key":"1580_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13578-023-01157-6","volume":"13","author":"B Cheng","year":"2023","unstructured":"Cheng B, Li L, Wu Y, Luo T, Tang C, Wang Q, et al. The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment. Cell Biosci. 2023;13:211.","journal-title":"Cell Biosci"},{"key":"1580_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121659","volume":"325","author":"B Cheng","year":"2023","unstructured":"Cheng B, Tang C, Xie J, Zhou Q, Luo T, Wang Q, et al. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis. Life Sci. 2023;325:121659.","journal-title":"Life Sci"},{"key":"1580_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-024-02962-8","volume":"43","author":"B Cheng","year":"2024","unstructured":"Cheng B, Li L, Luo T, Wang Q, Luo Y, Bai S, et al. Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1\/STAT4 pathway. J Exp Clin Cancer Res. 2024;43:67.","journal-title":"J Exp Clin Cancer Res"},{"key":"1580_CR29","volume":"25","author":"W Li","year":"2025","unstructured":"Li W, Shangguan W, Huang W, Zhao J, Zhu Y, Xie M, et al. Gut parabacteroides distasonis-derived indole-3-acetic acid promotes phospholipid remodeling and enhances ferroptosis sensitivity via the AhR-FASN axis in bladder cancer. Adv Sci. 2025;25:e4688.","journal-title":"Adv Sci"},{"key":"1580_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34871-9","volume":"13","author":"N Li","year":"2022","unstructured":"Li N, Liu Q, Han Y, Pei S, Cheng B, Xu J, et al. ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat Commun. 2022;13:7281.","journal-title":"Nat Commun"},{"key":"1580_CR31","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ccell.2023.05.016","volume":"41","author":"H Wang","year":"2023","unstructured":"Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, et al. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell. 2023;41:1345\u201362.","journal-title":"Cancer Cell"},{"key":"1580_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70082","volume":"6","author":"C Tang","year":"2025","unstructured":"Tang C, Peng S, Chen Y, Cheng B, Li S, Zhou J, et al. SHCBP1 is a novel regulator of PLK1 phosphorylation and promotes prostate cancer bone metastasis. MedComm. 2025;6:e70082.","journal-title":"MedComm"},{"key":"1580_CR33","doi-asserted-by":"publisher","first-page":"e011154","DOI":"10.1136\/jitc-2024-011154","volume":"13","author":"B Cheng","year":"2025","unstructured":"Cheng B, Wu J, Chen K, Li W, Yang J, Shangguan W, et al. Association of 5alpha-reductase inhibitor prescription with immunotherapy efficacy in metastatic renal cell carcinoma: a multicenter retrospective analysis. J Immunother Cancer. 2025;13:e011154.","journal-title":"J Immunother Cancer"},{"key":"1580_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/35077213","volume":"411","author":"GI Evan","year":"2001","unstructured":"Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342\u20138.","journal-title":"Nature"},{"key":"1580_CR35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","volume":"20","author":"TG Phan","year":"2020","unstructured":"Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20:398\u2013411.","journal-title":"Nat Rev Cancer"},{"key":"1580_CR36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/genes13050741","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun Y, Li H. Chimeric RNAs discovered by RNA sequencing and their roles in cancer and rare genetic diseases. Genes. 2022;13:741.","journal-title":"Genes"},{"key":"1580_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109747","volume":"75","author":"G Visci","year":"2020","unstructured":"Visci G, Tolomeo D, Agostini A, Traversa D, Macchia G, Storlazzi CT. CircRNAs and Fusion-circRNAs in cancer: New players in an old game. Cell Sig. 2020;75:109747.","journal-title":"Cell Sig"},{"key":"1580_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: Technologies and applications. Sig Transduct Target Ther. 2023;8:160.","journal-title":"Sig Transduct Target Ther"},{"key":"1580_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-022-01278-4","volume":"15","author":"H Xu","year":"2022","unstructured":"Xu H, Jiao D, Liu A, Wu K. Tumor organoids: applications in cancer modeling and potentials in precision medicine. J Hematol Oncol. 2022;15:58.","journal-title":"J Hematol Oncol"},{"key":"1580_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002895","author":"B Cheng","year":"2025","unstructured":"Cheng B, Yang J, Huang W, Luo T, Li L, Wu J, et al. Regulation of macrophage plasticity by circCCDC719-13 through HSP90 inhibition suppresses prostate cancer progression and metastasis: a translational study. Int J Surg. 2025. https:\/\/doi.org\/10.1097\/JS9.0000000000002895","journal-title":"Int J Surg"},{"key":"1580_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01999-9","volume":"23","author":"J Diao","year":"2024","unstructured":"Diao J, Jia Y, Dai E, Liu J, Kang R, Tang D, et al. Ferroptotic therapy in cancer: Benefits, side effects, and risks. Mol Cancer. 2024;23:89.","journal-title":"Mol Cancer"},{"key":"1580_CR42","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42:513\u201334.","journal-title":"Cancer Cell"},{"key":"1580_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Sig Transduct Target Ther. 2024;9:55.","journal-title":"Sig Transduct Target Ther"},{"key":"1580_CR44","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41392-023-01606-1","volume":"8","author":"S Sun","year":"2023","unstructured":"Sun S, Shen J, Jiang J, Wang F, Min J. Targeting ferroptosis opens new avenues for the development of novel therapeutics. Sig Transduct Target Ther. 2023;8:372.","journal-title":"Sig Transduct Target Ther"},{"key":"1580_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101081","volume":"74","author":"A Diaz-Jimenez","year":"2024","unstructured":"Diaz-Jimenez A, Ramos M, Helm B, Chocarro S, Frey DL, Agrawal S, et al. Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome. Drug Resist Updat. 2024;74:101081.","journal-title":"Drug Resist Updat"},{"key":"1580_CR46","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41585-023-00795-2","volume":"20","author":"N Pernigoni","year":"2023","unstructured":"Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M, et al. The potential role of the microbiota in prostate cancer pathogenesis and treatment. Nat Rev Urol. 2023;20:706\u201318.","journal-title":"Nat Rev Urol"},{"key":"1580_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21:47.","journal-title":"Mol Cancer"},{"key":"1580_CR48","doi-asserted-by":"publisher","first-page":"e164354","DOI":"10.1172\/JCI164354","volume":"133","author":"J Liu","year":"2023","unstructured":"Liu J, Zhang C, Xu D, Zhang T, Chang CY, Wang J, et al. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer. J Clin Invest. 2023;133:e164354.","journal-title":"J Clin Invest"},{"key":"1580_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105443","volume":"165","author":"M Alomari","year":"2021","unstructured":"Alomari M. TRIM21 - a potential novel therapeutic target in cancer. Pharmacol Res. 2021;165:105443.","journal-title":"Pharmacol Res"},{"key":"1580_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41418-021-00867-z","volume":"29","author":"W Gao","year":"2022","unstructured":"Gao W, Li Y, Liu X, Wang S, Mei P, Chen Z, et al. TRIM21 regulates pyroptotic cell death by promoting Gasdermin D oligomerization. Cell Death Differ. 2022;29:439\u201350.","journal-title":"Cell Death Differ"},{"key":"1580_CR51","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/cr.2016.95","volume":"26","author":"M Gao","year":"2016","unstructured":"Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26:1021\u201332.","journal-title":"Cell Res"},{"key":"1580_CR52","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.chembiol.2020.02.005","volume":"27","author":"J Liu","year":"2020","unstructured":"Liu J, Kuang F, Kroemer G, Klionsky DJ, Kang R, Tang D. Autophagy-dependent ferroptosis: machinery and regulation. Cell Chem Biol. 2020;27:420\u201335.","journal-title":"Cell Chem Biol"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01580-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01580-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01580-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:03:50Z","timestamp":1774868630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01580-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1038\/s41418-025-01580-x","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During final figure assembly, a panel within Figure S8F was inadvertently exported from an intermediate working folder and mistakenly placed in the composite figure.This correction does not affect the quantitative results, statistical analyses, figure legend, or the conclusions of the manuscript.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethical Review Committee of Sun Yat\u2013sen University for research involving human subjects. All human tissue samples were collected from patients who provided written informed consent. All animal experiments were conducted with approval from the Institutional Animal Care and Use Committee (IACUC) of Sun Yat\u2013sen University and were carried out in strict accordance with established ethical guidelines (SYSU-IACUC-2023-000989).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participant"}},{"value":"All participants involved in this study have given their informed consent for the publication of the data presented in this manuscript. This research adheres to ethical standards, and appropriate consent for publication has been obtained from all subjects. No personal identifying information is included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}